SynthesisCancer medicine2015
Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer.
Synthesis in Cancer medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- The Value of Dysregulated LncRNAs on Clinicopathology and Survival in Non-Small-Cell LungFrontiers in genetics · 2022Pooled it
- Diagnostic accuracy and prognostic applications of CYFRA 21-1 in head and neck cancer: A systematic review and meta-analysis.PloS one · 2019Pooled it
- Serum and tissue leptin in lung cancer: A meta-analysis.Oncotarget · 2017Pooled it
- Combined circulating tumor antigen model demonstrates additional prognostic value in first-line treatment of non-small cell lung cancer.Journal for immunotherapy of cancer · 2026Article
- Exosomal 3'tiRNA-PheGAA and interleukin-6 as novel biomarkers for non-invasive detection of NSCLC.Discover oncology · 2026Article
- AptoDetect™-Lung Assay as a Blood-Based Predictor of Advanced-Stage Lung Cancer in Patients with Lung-RADS 3-4 Pulmonary Nodules: A Multicenter Prospective Cohort Study.Biomedicines · 2026Article
- Serum Carcinoembryonic Antigen Levels Across Molecular Subtypes and Their Clinical and Prognostic Implications in Metastatic Non-Small Cell Lung Cancer.Medicina (Kaunas, Lithuania) · 2026Article
- Diagnostic value of serum biomarkers for identifying computed tomography abnormalities in male miners.Scientific reports · 2026Article
- Review of Existing Approaches and Potential Role of Pharmacometrics in the Interpretation of Prognostic Circulating Serum Biomarkers in Advanced NSCLC.Clinical and translational science · 2026Review
- Predictive value analysis of CEA, CA125 and CYFRA21-1 levels in evaluating the efficacy of tislelizumab combined with gemcitabine-cisplatin chemotherapy in patients with advanced non-small cell lung cancer.Oncology letters · 2026Article
- Lactate dehydrogenase to albumin ratio as a prognostic indicator for patients with resectable non-small cell lung cancer.Annals of medicine and surgery (2012) · 2025Article
- Development and validation of a multimodal radiomics-serum biomarker model for diagnosing solid pulmonary nodules via machine learning.Journal of thoracic disease · 2025Article
- Utility of serum CYFRA 21-1 as a prognostic biomarker in ALK-positive non-small cell lung cancer treated with ALK-TKIs: a retrospective cohort study.Translational lung cancer research · 2025Article
- Diagnostic Potential of Exosomal and Non-Exosomal Biomarkers in Lung Cancer: A Comparative Analysis Using a Rat Model of Lung Carcinogenesis.Non-coding RNA · 2025Article
- Assessing metabolic alterations and cancer biomarkers in athymic nude mice implanted with NSCLC spheroids.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Trajectories of perioperative serum CEA and non-small cell lung cancer prognosis: a retrospective longitudinal cohort study.Frontiers in oncology · 2025Article
- LungPanelNet: a machine learning-based approach for the early prediction and differentiation of non-small cell lung cancer.Frontiers in oncology · 2025Article
- Progression in Near-Infrared Fluorescence Imaging Technology for Lung Cancer Management.Biosensors · 2024Review
- CYFRA 21-1 predicts efficacy of combined chemoimmunotherapy in patients with advanced non-small cell lung cancer: a prospective observational study.Translational lung cancer research · 2024Article
- Different nodal upstaging rates and prognoses for patients with clinical T1N0M0 lung adenocarcinoma classified according to the presence of solid components in the lung and mediastinal windows.Journal of thoracic disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the study was to assess the clinical prognostic value of serum cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA) for non-small-cell lung cancer (NSCLC) patients. Literatures related to effects of serum CYFRA21-1 and CEA on the prognosis of lung cancer patients were retrieved from databases such as PubMed, Springer Link, Embase, Wanfang, and CNKI. Meta-analysis was carried out using RevMan 5.1 software. Ten literatures involving 1990 NSCLC patients were selected in this study. Total survive estimation merging hazard ratio (HR) in all NSCLC patients with high-level serum CYFRA21-1 was 1.64 (95% CI 1.46-1.84, P < 0.001) and that in all NSCLC patients with high level serum CEA was 1.46 (95% CI 1.28-1.65, P < 0.001). Serum CYFRA21-1 and CEA can be used as prognostic factors of NSCLC patients. Combinative detection of the two indices will be more reliable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.